|
1
|
Hay ED: An overview of
epithelio-mesenchymal transformation. Acta Anat (Basel). 154:8–20.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim J and Thiery JP:
Epithelial-mesenchymal transitions: Insights from development.
Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frisch SM, Farris JC and Pifer PM: Roles
of grainyhead-like transcription factors in cancer. Oncogene.
36:6067–6073. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He J, Feng C, Zhu H, Wu S, Jin P and Xu T:
Grainyhead-like 2 as a double-edged sword in development and
cancer. Am J Transl Res. 12:310–331. 2020.PubMed/NCBI
|
|
7
|
Chung VY, Tan TZ, Tan M, Wong MK, Kuay KT,
Yang Z, Ye J, Muller J, Koh CM, Guccione E, et al:
GRHL2-miR-200-ZEB1 maintains the epithelial status of
ovarian cancer through transcriptional regulation and histone
modification. Sci Rep. 6:199432016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cieply B, Farris J, Denvir J, Ford HL and
Frisch SM: Epithelial-mesenchymal transition and tumor suppression
are controlled by a reciprocal feedback loop between ZEB1 and
grainyhead-like-2. Cancer Res. 73:6299–6309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cieply B, Riley P IV, Pifer PM, Widmeyer
J, Addison JB, Ivanov AV, Denvir J and Frisch SM: Suppression of
the epithelial-mesenchymal transition by grainyhead-like-2. Cancer
Res. 72:2440–2453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farris JC, Pifer PM, Zheng L, Gottlieb E,
Denvir J and Frisch SM: Grainyhead-like 2 reverses the metabolic
changes induced by the oncogenic epithelial-mesenchymal transition:
Effects on anoikis. Mol Cancer Res. 14:528–538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishino H, Takano S, Yoshitomi H, Suzuki
K, Kagawa S, Shimazaki R, Shimizu H, Furukawa K, Miyazaki M and
Ohtsuka M: Grainyhead-like 2 (GRHL2) regulates epithelial
plasticity in pancreatic cancer progression. Cancer Med.
6:2686–2696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan X, Zhang R, Xie C, Gan M, Yao S, Yao
Y, Jin J, Han T, Huang Y, Gong Y, et al: GRHL2 suppresses
tumor metastasis via regulation of transcriptional activity of RhoG
in non-small cell lung cancer. Am J Transl Res. 9:4217–4226.
2017.PubMed/NCBI
|
|
13
|
Shen J, Lv X and Zhang L: GRHL2
acts as an anti-oncogene in bladder cancer by regulating ZEB1 in
epithelial-mesenchymal transition (EMT) process. Onco Targets Ther.
13:2511–2522. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Werner S, Frey S, Riethdorf S, Schulze C,
Alawi M, Kling L, Vafaizadeh V, Sauter G, Terracciano L, Schumacher
U, et al: Dual roles of the transcription factor grainyhead-like 2
(GRHL2) in breast cancer. J Biol Chem. 288:22993–23008.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiang J, Fu X, Ran W and Wang Z:
Grhl2 reduces invasion and migration through inhibition of
TGFβ-induced EMT in gastric cancer. Oncogenesis. 6:e2842017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiang X, Deng Z, Zhuang X, Ju S, Mu J,
Jiang H, Zhang L, Yan J, Miller D and Zhang HG: Grhl2
determines the epithelial phenotype of breast cancers and promotes
tumor progression. PLoS One. 7:e507812012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang Z, Wu D, Chen Y, Min Z and Quan Y:
GRHL2 inhibits colorectal cancer progression and metastasis
via oppressing epithelial-mesenchymal transition. Cancer Biol Ther.
20:1195–1205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen W, Kang KL, Alshaikh A, Varma S, Lin
YL, Shin KH, Kim R, Wang CY, Park NH, Walentin K, et al:
Grainyhead-like 2 (GRHL2) knockout abolishes oral cancer
development through reciprocal regulation of the MAP kinase and
TGF-β signaling pathways. Oncogenesis. 7:382018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faddaoui A, Sheta R, Bachvarova M, Plante
M, Gregoire J, Renaud MC, Sebastianelli A, Gobeil S, Morin C, Ghani
K and Bachvarov D: Suppression of the grainyhead transcription
factor 2 gene (GRHL2) inhibits the proliferation, migration,
invasion and mediates cell cycle arrest of ovarian cancer cells.
Cell Cycle. 16:693–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu F, He Z, Sun C and Rong D: Knockdown of
GRHL2 inhibited proliferation and induced apoptosis of
colorectal cancer by suppressing the PI3K/Akt pathway. Gene.
700:96–104. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quan Y, Jin R, Huang A, Zhao H, Feng B,
Zang L and Zheng M: Downregulation of GRHL2 inhibits the
proliferation of colorectal cancer cells by targeting ZEB1. Cancer
Biol Ther. 15:878–887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jolly MK, Tripathi SC, Jia D, Mooney SM,
Celiktas M, Hanash SM, Mani SA, Pienta KJ, Ben-Jacob E and Levine
H: Stability of the hybrid epithelial/mesenchymal phenotype.
Oncotarget. 7:27067–27084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai L, Lin S, Girard L, Zhou Y, Yang L, Ci
B, Zhou Q, Luo D, Yao B, Tang H, et al: LCE: An open web portal to
explore gene expression and clinical associations in lung cancer.
Oncogene. 38:2551–2564. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato M, Shay JW and Minna JD: Immortalized
normal human lung epithelial cell models for studying lung cancer
biology. Respir Investig. 58:344–354. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sato M, Vaughan MB, Girard L, Peyton M,
Lee W, Shames DS, Ramirez RD, Sunaga N, Gazdar AF, Shay JW and
Minna JD: Multiple oncogenic changes (K-RAS(V12), p53 knockdown,
mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer
a full malignant phenotype on human bronchial epithelial cells.
Cancer Res. 66:2116–2128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phelps RM, Johnson BE, Ihde DC, Gazdar AF,
Carbone DP, McClintock PR, Linnoila RI, Matthews MJ, Bunn PA Jr,
Carney D, et al: NCI-navy medical oncology branch cell line data
base. J Cell Biochem Suppl. 24:32–91. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ramirez RD, Sheridan S, Girard L, Sato M,
Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, et al:
Immortalization of human bronchial epithelial cells in the absence
of viral oncoproteins. Cancer Res. 64:9027–9034. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van Kuppeveld FJ, Johansson KE, Galama JM,
Kissing J, Bölske G, van der Logt JT and Melchers WJ: Detection of
mycoplasma contamination in cell cultures by a mycoplasma
group-specific PCR. Appl Environ Microbiol. 60:149–152. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato M, Girard L, Sekine I, Sunaga N,
Ramirez RD, Kamibayashi C and Minna JD: Increased expression and no
mutation of the Flap endonuclease (FEN1) gene in human lung cancer.
Oncogene. 22:7243–7246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schindelin J, Arganda-Carreras I, Frise E,
Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S,
Schmid B, et al: Fiji: An open-source platform for biological-image
analysis. Nat Methods. 9:676–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to imageJ: 25 Years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McMillan EA, Ryu MJ, Diep CH, Mendiratta
S, Clemenceau JR, Vaden RM, Kim JH, Motoyaji T, Covington KR,
Peyton M, et al: Chemistry-first approach for nomination of
personalized treatment in lung cancer. Cell. 173:864–878.e29. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Das AK, Sato M, Story MD, Peyton M, Graves
R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD and Nirodi CS:
Non-small-cell lung cancers with kinase domain mutations in the
epidermal growth factor receptor are sensitive to ionizing
radiation. Cancer Res. 66:9601–9608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sunaga N, Imai H, Shimizu K, Shames DS,
Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, et
al: Oncogenic KRAS-induced interleukin-8 overexpression promotes
cell growth and migration and contributes to aggressive phenotypes
of non-small cell lung cancer. Int J Cancer. 130:1733–1744. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen L, Liu H, Ji Y, Ma Z, Shen K,
Shangguan X, Qian H, Zhao Y, Pan CW and Xue W: Downregulation of
SHMT2 promotes the prostate cancer proliferation and metastasis by
inducing epithelial-mesenchymal transition. Exp Cell Res.
415:1131382022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He F, Feng G, Ma N, Midorikawa K, Oikawa
S, Kobayashi H, Zhang Z, Huang G, Takeuchi K and Murata M: GDF10
inhibits cell proliferation and epithelial-mesenchymal transition
in nasopharyngeal carcinoma by the transforming growth
factor-β/Smad and NF-κB pathways. Carcinogenesis. 43:94–103.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang W, Huang H, Xiao Y, Wang L, Zhang T,
Fang X and Xia X: UBE2T is upregulated, predicts poor prognosis,
and promotes cell proliferation and invasion by promoting
epithelial-mesenchymal transition via inhibiting autophagy in an
AKT/mTOR dependent manner in ovarian cancer. Cell Cycle.
21:780–791. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ding C, Luo J, Li L, Li S, Yang L, Pan H,
Liu Q, Qin H, Chen C and Feng J: Gab2 facilitates
epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling
in colorectal cancer. J Exp Clin Cancer Res. 35:52016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Karimi Roshan M, Soltani A, Soleimani A,
Rezaie Kahkhaie K, Afshari AR and Soukhtanloo M: Role of AKT and
mTOR signaling pathways in the induction of epithelial-mesenchymal
transition (EMT) process. Biochimie. 165:229–234. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu M, Cao FL, Li N, Gao X, Su X and Jiang
X: Leptin induces epithelial-to-mesenchymal transition via
activation of the ERK signaling pathway in lung cancer cells. Oncol
Lett. 16:4782–4788. 2018.PubMed/NCBI
|
|
45
|
Cook SJ, Stuart K, Gilley R and Sale MJ:
Control of cell death and mitochondrial fission by ERK1/2 MAP
kinase signalling. FEBS J. 284:4177–4195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brix N, Samaga D, Belka C, Zitzelsberger H
and Lauber K: Analysis of clonogenic growth in vitro. Nat Protoc.
16:4963–4991. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Franken NAP, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen AF, Liu AJ, Krishnakumar R, Freimer
JW, DeVeale B and Blelloch R: GRHL2-Dependent enhancer
switching maintains a pluripotent stem cell transcriptional
subnetwork after exit from naive pluripotency. Cell Stem Cell.
23:226–238.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gao X, Bali AS, Randell SH and Hogan BL:
GRHL2 coordinates regeneration of a polarized mucociliary
epithelium from basal stem cells. J Cell Biol. 211:669–682. 2015.
View Article : Google Scholar : PubMed/NCBI
|
